Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 4Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Recurrence 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 13pembrolizumab 8Brentuximab Vedotin 8fludarabine 7Nivolumab 7Whole-Body Irradiation 6Specimen Handling 6Mycophenolic Acid 6Gemcitabine 6Etoposide 6Doxorubicin 6Dacarbazine 6fludarabine phosphate 5Vinblastine 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Dexamethasone 5Stem Cell Transplantation 4Cytarabine 4Vinorelbine 3Tacrolimus 3Magnetic Resonance Spectroscopy 3Cyclosporine 3Carmustine 3Blood Specimen Collection 3thymoglobulin 2polatuzumab vedotin 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hodgkin Disease × polatuzumab vedotin × Clear all
NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M.D. Anderson Cancer Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical College

Phase 1/2 Recruiting
20 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡